Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 3/2013

01-09-2013 | Original Article

Prescribing pattern of antidiabetic drugs and achievement of glycemic control in T2DM patients tertiary care hospital in North India

Authors: Ethiraj Dhanaraj, Amit D. Raval, Rajbharm Yadav, Anil Bhansali, Pramil Tiwari

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2013

Login to get access

Abstract

Study was undertaken to identify patterns of antidiabetic drugs prescribing in established type 2 diabetes mellitus. Patients with established T2DM who attended the endocrinology Outpatient Clinic in Postgraduate Institute of Medical Education and Research, Chandigarh, India were evaluated for social, demographical and clinical variables and medications. 1185 established T2DM patients were assessed. Metformin was the most commonly prescribed drug [827 (70 %)], followed by insulin [627 (53 %)], sulfonylureas [520 (44 %)], and pioglitazone [329 (28 %)]. The most frequently prescribed monotherapy was insulin [214 (62 %)], followed by metformin in 81 (23 %), sulfonylurea in 49 (14 %) and pioglitazone in 4 (1 %) patients. 704 (59 %) treated patients had uncontrolled hyperglycemia. Family history (OR 1.76, 95%CI 1.18, 2.64), diabetes duration (OR 2.62, 95 % CI 2.05, 3.36), HbA1c (OR 1.25, 95%CI 1.01, 1.50), neuropathy(OR 1.57, 95 % CI, 1.14, 2.2), nephropathy(OR 1.77, 95 % CI 1.40, 2.24), retinopathy (OR 1.97, 95 % CI 1.63, 2.40), coronary arterial disease (CAD) (OR 1.57, 95 % CI, 1.14, 2.2) and diabetic foot (OR 1.62, 95 % CI 1.12, 2.40) were all significantly associated with insulin therapy. Obese and overweight patients were prescribed oral antidiabetic drugs. Medication use was consistent with practice guidelines in T2DM, even though the outcome did not reach the goal.
Literature
1.
go back to reference Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–9.PubMedCrossRef Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–9.PubMedCrossRef
2.
go back to reference Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–52.PubMedCrossRef Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–52.PubMedCrossRef
3.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCrossRef
4.
go back to reference Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001;24:1167–74.PubMedCrossRef Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001;24:1167–74.PubMedCrossRef
5.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef
6.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMedCrossRef
7.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef
8.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef
9.
go back to reference Cobitz AR, Ambery P. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care. 2009;32:e58.PubMedCrossRef Cobitz AR, Ambery P. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care. 2009;32:e58.PubMedCrossRef
10.
11.
go back to reference Indian diabetes guidelines. J Assoc Physicians India. 2002;50:295. Indian diabetes guidelines. J Assoc Physicians India. 2002;50:295.
12.
go back to reference Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMedCrossRef Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMedCrossRef
13.
go back to reference Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225–30.PubMedCrossRef Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225–30.PubMedCrossRef
14.
go back to reference Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–61.PubMedCrossRef Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–61.PubMedCrossRef
15.
go back to reference Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–5.PubMed Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–5.PubMed
16.
go back to reference Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077–80.PubMed Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077–80.PubMed
17.
go back to reference Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786–806. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786–806.
18.
go back to reference Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet. 2004;364:423–8.PubMedCrossRef Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet. 2004;364:423–8.PubMedCrossRef
19.
go back to reference Secnik K, Yurgin N, Lage MJ, McDonald-Everett C. Patient characteristics, glycemic control, and the use of antidiabetic agents among individuals diagnosed with type 2 diabetes: Evidence from the UK. . ISPOR European Meeting; 2005 October 2005. Secnik K, Yurgin N, Lage MJ, McDonald-Everett C. Patient characteristics, glycemic control, and the use of antidiabetic agents among individuals diagnosed with type 2 diabetes: Evidence from the UK. . ISPOR European Meeting; 2005 October 2005.
20.
go back to reference Yurgin N, Secnik K, Lage MJ, editor. Type 2 diabetes in Germany: Prevalence and medication use. ISPOR European Meeting, October 2005. Yurgin N, Secnik K, Lage MJ, editor. Type 2 diabetes in Germany: Prevalence and medication use. ISPOR European Meeting, October 2005.
21.
go back to reference Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care. 2003;26:1852–5.PubMedCrossRef Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001. Diabetes Care. 2003;26:1852–5.PubMedCrossRef
22.
go back to reference Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–51.PubMedCrossRef Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol. 2005;60:543–51.PubMedCrossRef
23.
go back to reference Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG. Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract. 2005;6:13.PubMedCrossRef Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG. Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract. 2005;6:13.PubMedCrossRef
24.
go back to reference Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26:1847–51.PubMedCrossRef Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26:1847–51.PubMedCrossRef
26.
go back to reference Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Saf. 1999;21:7–22.PubMedCrossRef Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Saf. 1999;21:7–22.PubMedCrossRef
27.
go back to reference Lund SS, Vaag AA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al. Diabetes Care. 2009;32:e90–1.PubMedCrossRef Lund SS, Vaag AA. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al. Diabetes Care. 2009;32:e90–1.PubMedCrossRef
28.
go back to reference Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.PubMedCrossRef Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.PubMedCrossRef
29.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
30.
go back to reference Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–25.PubMedCrossRef Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–25.PubMedCrossRef
31.
go back to reference Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–8.PubMedCrossRef Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–8.PubMedCrossRef
32.
go back to reference Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389–96.PubMedCrossRef Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389–96.PubMedCrossRef
33.
go back to reference Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–82.PubMedCrossRef Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–82.PubMedCrossRef
34.
go back to reference Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600–6.PubMedCrossRef Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600–6.PubMedCrossRef
Metadata
Title
Prescribing pattern of antidiabetic drugs and achievement of glycemic control in T2DM patients tertiary care hospital in North India
Authors
Ethiraj Dhanaraj
Amit D. Raval
Rajbharm Yadav
Anil Bhansali
Pramil Tiwari
Publication date
01-09-2013
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2013
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-013-0123-5

Other articles of this Issue 3/2013

International Journal of Diabetes in Developing Countries 3/2013 Go to the issue